RhoVac recruits Steven Glazer as Medical Director
RhoVac AB (“RhoVac”) announced today, September 18, 2018, that the company has recruited Dr. Steven Glazer to the position of Medical Director (MD), commencing immediately.
Steven Glazer has been recruited as Medical Director of RhoVac. Steven has extensive expertise and long-term international experience in both strategic and operational clinical development in the pharmaceutical and biotechnology industry in both the US and Europe. Steven's previous assignments include Senior Vice President Development at Bioinvent International AB, Director of Haematology at Novo Nordisk AS and Chief Medical Officer at Hansa Medical AB. In parallel with the part-time assignment at RhoVac, Steven continues his work as Chief Medical Officer at Idogen AB and Board Member of Immunicum AB. Steven holds a doctorate in medicine from the University of Copenhagen and is trained in internal medicine.
Comments from MD Steven Glazer
-RhoVac has a very interesting concept for treatment of cancer and the positive results from the clinical phase I/II study look very promising for the further development of the project. I look forward to working on progressing the project into a Phase IIb clinical trial.
Comments from RhoVac´s CEO, Anders Ljungqvist
-At the rights issue completed earlier this year, the company prioritized business development as well as clinical and regulatory development. Business development is ongoing in collaboration with Colpman Consulting and with the recruitment of Steven, we will further strengthen the clinical and regulatory part of the organization. Hereby we ensure that the work on project development continues as planned and thus the value of the company is optimized. We are looking forward to having Steven in the RhoVac team.
For more information, please contact:
Anders Ljungqvist – VD, RhoVac AB
Phone: +45 4083 2365
E-mail: alj@rhovac.com
This is an English version of an original Swedish press release communicated by RhoVac AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that RhoVac AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 18 September 2018.
About RhoVac AB
RhoVac AB conducts research and development of immunotherapeutic drugs. The company's main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac's top-line results from the clinical phase I / II study has been published I August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight Trade Market, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.